EVOLVE 104 antibody-drug conjugate

N/A

Report date: 2025/08/19 10:06:11
First In Class

Base Information

Drug NameEVOLVE 104 antibody-drug conjugate
Drug Alias NameEVOLVE-104 ADCEVOLVE-104
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionRetinoic Acid Early Transcript 1L modulatorsUL16 Binding Protein 2 modulators
TargetsRetinoic Acid Early Transcript 1LUL16 Binding Protein 2
Therapy Area/IndicationsPenile Squamous Cell CarcinomaSolid tumoursUrinary Bladder Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEvolveImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEvolveImmune United IncEvolveImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPenile Squamous Cell CarcinomaSolid tumoursUrinary Bladder Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A